Dataset for reporting of carcinoma of the urethra (in urethrectomy specimens): recommendations from the International Collaboration on Cancer Reporting (ICCR).
checklist
dataset
protocol
structured report
synoptic report
tumours
urethral carcinoma
urothelial
Journal
Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
pubmed:
23
4
2019
medline:
29
2
2020
entrez:
23
4
2019
Statut:
ppublish
Résumé
The International Collaboration on Cancer Reporting (ICCR) is a not-for-profit organisation sponsored by the Royal Colleges of Pathologists of Australasia and the United Kingdom, the College of American Pathologists, the Canadian Association of Pathologists in association with the Canadian Partnership Against Cancer, the European Society of Pathology, the American Society of Clinical Pathology and the Faculty of Pathology, Royal College of Physicians of Ireland. Its goal is to produce standardised, internationally agreed-upon, evidence-based datasets for cancer pathology reporting throughout the world. This paper describes the development of a cancer dataset by the multidisciplinary ICCR expert panel for the reporting of carcinoma of the urethra in urethrectomy specimens. The dataset is composed of 'required' (mandatory) and 'recommended' (non-mandatory) elements, which are based on a review of the most recent evidence and supported by explanatory commentary. Fourteen required elements and eight recommended elements were agreed by the international dataset authoring committee to represent the essential/required (core) and recommended (non-core) information for the reporting of carcinoma of the urethra in urethrectomy specimens. Use of an internationally agreed, structured pathology dataset for reporting carcinoma of the urethra (in urethrectomy specimens) will provide the necessary information for optimal patient management, will facilitate consistent data collection and will provide valuable data for research and international benchmarking. The dataset will be valuable for those countries and institutions that are not in a position to develop their own datasets.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
453-467Informations de copyright
© 2019 John Wiley & Sons Ltd.
Références
Royal College of Pathologists UK. Cancer datasets and tissue pathways. 2010-2018. Available at: https://www.rcpath.org/profession/guidelines/cancer-datasets-and-tissue-pathways.html (accessed February 2019).
College of American Pathologists. Cancer protocol templates. August 2018. Available at: http://www.cap.org/web/oracle/webcenter/portalapp/pagehierarchy/cancer_protocol_templates.jspx?_afrLoop=212779956262482#!%40%40%3F_afrLoop%3D212779956262482%26_adf.ctrl-state%3Da98ka87ex_4 (accessed February 2019).
Royal College of Pathologists of Australia. Cancer protocols. 2010-2018. Available at: https://www.rcpa.edu.au/Library/Practising-Pathology/Structured-Pathology-Reporting-of-Cancer/Cancer-Protocols (accessed February 2019).
Kench JG, Delahunt B, Griffiths DF et al. Data set for reporting of prostate carcinoma in radical prostatectomy specimens: recommendations from the International Collaboration on Cancer Reporting. Histopathology 2013; 62; 203-218.
McCluggage WG, Colgan T, Duggan M et al. Data set for reporting of endometrial carcinomas: recommendations from the International Collaboration on Cancer Reporting (ICCR) between United Kingdom, United States, Canada, and Australasia. Int. J. Gynecol. Pathol. 2013; 32; 45-65.
Jones KD, Churg A, Henderson DW et al. Data set for reporting of lung carcinomas: recommendations from International Collaboration on Cancer Reporting. Arch. Pathol. Lab. Med. 2013; 137; 1054-1062.
Scolyer RA, Judge MJ, Evans A et al. Data set for pathology reporting of cutaneous invasive melanoma. Recommendations from the International Collaboration on Cancer Reporting (ICCR). Am. J. Surg. Pathol. 2013; 37; 1797-1814.
McCluggage WG, Judge MJ, Clarke BA et al. Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Mod. Pathol. 2015; 28; 1101-1122.
Churg A, Attanoos R, Borczuk AC et al. Data set for reporting of malignant mesothelioma of the pleura or peritoneum: recommendations from the International Collaboration on Cancer Reporting (ICCR). Arch. Pathol. Lab. Med. 2016; 140; 1104-1110.
Nicholson AG, Detterbeck F, Marx A et al. Data set for reporting of thymic epithelial tumours: recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology 2017; 70; 522-538.
McCluggage WG, Judge MJ, Alvarado-Cabrero I et al. Data set for the reporting of carcinomas of the cervix: recommendations from the International Collaboration on Cancer Reporting (ICCR). Int. J. Gynecol. Pathol. 2018; 37; 205-228.
Moch H, Humphrey PA, Ulbright TM, Reuter RE. WHO classification of tumours of the urinary system and male genital organs. Lyon: IARC Press, 2016.
International Collaboration on Cancer Reporting (2017-2018). Data sets for urinary/male genital. Available at: http://www.iccr-cancer.org/datasets/published-datasets/urinary-male-genital (accessed February 2019).
Merlin T, Weston A, Tooher R. Extending an evidence hierarchy to include topics other than treatment: revising the Australian ‘levels of evidence’. BMC Med. Res. Methodol. 2009; 9; 34.
Grignon D, Brimo F, Comperat E et al. Urinary tract carcinoma, histopathology reporting guide, biopsy and transurethral resection specimen. 1st ed. Sydney: International Collaboration on Cancer Reporting, 2018.
Corbishley C, Chaux A, Colecchia M et al. Carcinoma of the penis and distal urethra histopathology reporting guide. 1st ed. Sydney: International Collaboration on Cancer Reporting, 2017.
Rabbani F. Prognostic factors in male urethral cancer. Cancer 2011; 117; 2426-2434.
Gakis G, Ali-El-Dein B, Babjuk M et al. Urethral recurrence in women with orthotopic bladder substitutes: a multi-institutional study. Urol. Oncol. 2015; 33; 204.e17-204.e23.
Chan Y, Fisher P, Tilki D, Evans CP. Urethral recurrence after cystectomy: current preventative measures, diagnosis and management. BJU Int. 2016; 117; 563-569.
Gakis G, Witjes JA, Comperat E et al. EAU guidelines on primary urethral carcinoma. Eur. Urol. 2013; 64; 823-830.
Soave A, John LM, Dahlem R et al. The impact of tumor diameter and tumor necrosis on oncologic outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy. Urology 2015; 86; 92-98.
Dinney CP, Johnson DE, Swanson DA, Babaian RJ, von Eschenbach AC. Therapy and prognosis for male anterior urethral carcinoma: an update. Urology 1994; 43; 506-514.
Gheiler EL, Tefilli MV, Tiguert R, de Oliveira JG, Pontes JE, Wood DP Jr. Management of primary urethral cancer. Urology 1998; 52; 487-493.
Dalbagni G, Zhang ZF, Lacombe L, Herr HW. Male urethral carcinoma: analysis of treatment outcome. Urology 1999; 53; 1126-1132.
Gakis G, Morgan TM, Daneshmand S et al. Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: results of the international collaboration on primary urethral carcinoma. Ann. Oncol. 2015; 26; 1754-1759.
Johnson DE, O’Connell JR. Primary carcinoma of female urethra. Urology 1983; 26; 1754-1759.
Meis JM, Ayala AG, Johnson DE. Adenocarcinoma of the urethra in women. A clinicopathologic study. Cancer 1987; 60; 1038-1052.
Roberts TW, Melicow MM. Pathology and natural history of urethral tumors in females: review of 65 cases. Urology 1977; 10; 583-589.
Oliva E, Young RH. Clear cell adenocarcinoma of the urethra: a clinicopathologic analysis of 19 cases. Mod. Pathol. 1996; 9; 513-520.
Herawi M, Drew PA, Pan CC, Epstein JI. Clear cell adenocarcinoma of the bladder and urethra: cases diffusely mimicking nephrogenic adenoma. Hum. Pathol. 2010; 41; 594-601.
Kim SJ, MacLennan GT. Tumors of the male urethra. J. Urol. 2005; 174; 312.
Amin MB, Young RH. Primary carcinomas of the urethra. Semin. Diagn. Pathol. 1997; 14; 147-160.
Tregnago AC, Epstein JI. Skene’s glands adenocarcinoma: a series of 4 cases. Am. J. Surg. Pathol. 2018; 42; 1513-1521.
Bourque JL, Charghi A, Gauthier GE, Drouin G, Charbonneau J. Primary carcinoma of Cowper’s gland. J. Urol. 1970; 103; 758-761.
Syvänen KT, Taimen P, Salminen A, Kuusisto K, Boström PJ. Bulbourethral gland adenocarcinoma in a 25-year-old man without comorbidities: radical resection of proximal urethrae with Mitrofanoff-type appendicovesicostomy. Scand. J. Urol. 2014; 48; 405-409.
Raspollini MR, Carini M, Montironi R, Cheng L, Lopez-Beltran A. Mucinous adenocarcinoma of the male urethra: a report of two cases. Anal. Quant. Cytopathol. Histopathol. 2015; 37; 267-272.
Amin MB, Edge S, Greene FL et al. eds. AJCC cancer staging manual. 8th ed. New York: Springer, 2017.
Eble JN, Sauter G, Epstein JI, Sesterhenn IA. World Health Organisation classification of tumours. Pathology and genetics of tumours of the urinary system and male genital organs. Lyon: IARC Press, 2004.
Alexiev BA, Tavora F. Histology and immunohistochemistry of clear cell adenocarcinoma of the urethra: histogenesis and diagnostic problems. Virchows Arch. 2013; 462; 193-201.
Mehra R, Vats P, Kalyana-Sundaram S et al. Primary urethral clear cell adenocarcinoma: comprehensive analysis by surgical pathology, cytopathology, and next-generation sequencing. Am. J. Pathol. 2014; 184; 584-591.
Sung MT, Zhang S, MacLennan GT et al. Histogenesis of clear cell adenocarcinoma in the urinary tract: evidence of urothelial origin. Clin. Cancer Res. 2008; 14; 1947-1955.
Gilcrease MZ, Delgado R, Vuitch F, Albores-Saavedra J. Clear cell adenocarcinoma and nephrogenic adenoma of the urethra and urinary bladder: a histopathologic and immunohistochemical comparison. Hum. Pathol. 1998; 29; 1451-1456.
Drew PA, Murphy WM, Civantos F, Speights VO. The histogenesis of clear cell adenocarcinoma of the lower urinary tract. Case series and review of the literature. Hum. Pathol. 1996; 27; 248-252.
Oliva E, Amin MB, Jimenez R, Young RH. Clear cell carcinoma of the urinary bladder: a report and comparison of four tumors of mullerian origin and nine of probable urothelial origin with discussion of histogenesis and diagnostic problems. Am. J. Surg. Pathol. 2002; 26; 190-197.
Tong GX, Weeden EM, Hamele-Bena D et al. Expression of PAX8 in nephrogenic adenoma and clear cell adenocarcinoma of the lower urinary tract: evidence of related histogenesis? Am. J. Surg. Pathol. 2008; 32; 1380-1387.
Vang R, Whitaker BP, Farhood AI, Silva EG, Ro JY, Deavers MT. Immunohistochemical analysis of clear cell carcinoma of the gynecologic tract. Int. J. Gynecol. Pathol. 2001; 20; 252-259.
Osunkoya AO, Epstein JI. Primary mucin-producing urothelial-type adenocarcinoma of prostate: report of 15 cases. Am. J. Surg. Pathol. 2007; 31; 1323-1329.
Harari SE, Cheng L, Osunkoya AO. Primary mucinous adenocarcinoma of the female urethra: a contemporary clinicopathologic analysis. Hum. Pathol. 2016; 47; 132-137.
Suzuki K, Morita T, Tokue A. Primary signet ring cell carcinoma of female urethra. Int. J. Urol. 2001; 8; 509-512.
Reis LO, Billis A, Ferreira FT, Ikari LY, Stellini RF, Ferreira U. Female urethral carcinoma: evidences to origin from Skene’s glands. Urol. Oncol. 2011; 29; 218-223.
Massari F, Ciccarese C, Modena A et al. Adenocarcinoma of the paraurethral glands: a case report. Histol. Histopathol. 2014; 29; 1295-1303.
Zhang M, Pettaway C, Vikram R, Tamboli P. Adenoid cystic carcinoma of the urethra/Cowper’s gland with concurrent high-grade prostatic adenocarcinoma: a detailed clinicopathologic case report and review of the literature. Hum. Pathol. 2016; 58; 138-144.
Choong NW, Quevedo JF, Kaur JS. Small cell carcinoma of the urinary bladder. The Mayo Clinic experience. Cancer 2005; 103; 1172-1178.
Siefker-Radtke AO, Dinney CP, Abrahams NA et al. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. J. Urol. 2004; 172; 481-484.
Mackey JR, Au HJ, Hugh J, Venner P. Genitourinary small cell carcinoma: determination of clinical and therapeutic factors associated with survival. J. Urol. 1998; 159; 1624-1629.
Lynch SP, Shen Y, Kamat A et al. Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. Eur. Urol. 2013; 64; 307-313.
Clark PE, Agarwal N, Biagioli MC et al. Bladder cancer. J. Natl Compr. Canc. Netw. 2013; 11; 446-475.
National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Bladder Cancer. 2018. Available at: https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf (accessed February 2019).
Yoo KH, Kim GY, Kim TG, Min GE, Lee HL. Primary small cell neuroendocrine carcinoma of the female urethra. Pathol. Int. 2009; 59; 601-603.
Kanagarajah P, Ayyathurai R, Saleem U, Manoharan M. Small cell carcinoma arising from the bulbar urethra: a case report and literature review. Urol. Int. 2012; 88; 477-479.
Amin MB. Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications. Mod. Pathol. 2009; 22(Suppl. 2); S96-S118.
Lopez-Beltran A, Cheng L. Histologic variants of urothelial carcinoma: differential diagnosis and clinical implications. Hum. Pathol. 2006; 37; 1371-1388.
Linder BJ, Frank I, Cheville JC et al. Outcomes following radical cystectomy for nested variant of urothelial carcinoma: a matched cohort analysis. J. Urol. 2013; 189; 1670-1675.
Lopez-Beltran A, Cheng L, Montironi R et al. Clinicopathological characteristics and outcome of nested carcinoma of the urinary bladder. Virchows Arch. 2014; 465; 199-205.
Xylinas E, Rink M, Robinson BD et al. Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. Eur. J. Cancer 2013; 49; 1889-1897.
Kim SP, Frank I, Cheville JC et al. The impact of squamous and glandular differentiation on survival after radical cystectomy for urothelial carcinoma. J. Urol. 2012; 188; 405-409.
Hansel DE, Amin MB, Comperat E et al. A contemporary update on pathology standards for bladder cancer: transurethral resection and radical cystectomy specimens. Eur. Urol. 2013; 63; 321-332.
Grignon D, Brimo F, Comperat E et al. Urinary tract carcinoma, histopathology reporting guide, biopsy and transurethral resection specimen. 1st ed. Sydney: International Collaboration on Cancer Reporting, 2018.
Shah JB, McConkey DJ, Dinney CP. New strategies in muscle-invasive bladder cancer: on the road to personalized medicine. Clin. Cancer Res. 2011; 17; 2608-2612.
Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am. J. Surg. Pathol. 1998; 22; 1435-1448.
Amin MB, Smith SC, Reuter VE et al. Update for the practicing pathologist: the International Consultation On Urologic Disease-European Association of Urology consultation on bladder cancer. Mod. Pathol. 2015; 28; 612-630.
Protocol for the Examination of Specimens from Patients with Carcinoma of the Urethra and Periurethral Glands. College of American Pathologists. 2017. Available at: http://www.cap.org/ShowProperty?nodePath=/UCMCon/ContributionFolders/WebContent/pdf/cp-urethra-17protocol-4011.pdf(accessed October 2018).
May M, Brookman-Amissah S, Roigas J et al. Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications. Eur. Urol. 2010; 57; 850-858.
Cheng L, Neumann RM, Nehra A, Spotts BE, Weaver AL, Bostwick DG. Cancer heterogeneity and its biologic implications in the grading of urothelial carcinoma. Cancer 2000; 88; 1663-1670.
Billis A, Carvalho RB, Mattos AC et al. Tumor grade heterogeneity in urothelial bladder carcinoma - proposal of a system using combined numbers. Scand. J. Urol. Nephrol. 2001; 35; 275-279.
Reis LO, Taheri D, Chaux A et al. Significance of a minor high-grade component in a low-grade noninvasive papillary urothelial carcinoma of bladder. Hum. Pathol. 2016; 47; 20-25.
Gofrit ON, Pizov G, Shapiro A et al. Mixed high and low grade bladder tumors - are they clinically high or low grade? J. Urol. 2014; 191; 1693-1696.
Lopez-Beltran A, Bassi PF, Pavone-Macaluso M, Montironi R. Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis. A joint proposal of the European Society of Uropathology and the Uropathology Working Group. Virchows Arch. 2004; 445; 103-110.
Babjuk M, Burger M, Zigeuner R et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur. Urol. 2013; 64; 639-653.
The Royal College of Pathologists (RCPath). Data set for tumours of the urinary collecting system (renal pelvis, ureter, urinary bladder and urethra). 2013. Available at: https://www.rcpath.org/resourceLibrary/dataset-for-tumours-of-the-urinary-collecting-system-renal-pelvis-ureter-urinary-bladder-and-urethra.html (accessed February 2019).
Harnden P. A critical appraisal of the classification of urothelial tumours: time for a review of the evidence and a radical change? BJU Int. 2007; 99; 723-725.
Sylvester RJ, van der Meijden AP, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 2006; 49; 466-465.
Mikulowski P, Hellsten S. T1 G1 urinary bladder carcinoma: fact or fiction? Scand. J. Urol. Nephrol. 2005; 39; 135-137.
van Rhijn BW, Musquera M, Liu L et al. Molecular and clinical support for a four-tiered grading system for bladder cancer based on the WHO 1973 and 2004 classifications. Mod. Pathol. 2015; 28; 695-705.
Kruger S, Thorns C, Bohle A, Feller AC. Prognostic significance of a grading system considering tumor heterogeneity in muscle-invasive urothelial carcinoma of the urinary bladder. Int. Urol. Nephrol. 2003; 35; 169-173.
Cao D, Vollmer RT, Luly J et al. Comparison of 2004 and 1973 World Health Organisation grading systems and their relationship to pathologic staging for predicting long-term prognosis in patients with urothelial carcinoma. Urology 2010; 76; 593-599.
Otto W, Denzinger S, Fritsche HM et al. The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer. BJU Int. 2011; 107; 404-408.
Amin MB, McKenney JK, Paner GP et al. ICUD-EAU International Consultation on Bladder Cancer 2012: Pathology. Eur. Urol. 2013; 63; 16-35.
Wasco MJ, Daignault S, Bradley D, Shah RB. Nested variant of urothelial carcinoma: a clinicopathologic and immunohistochemical study of 30 pure and mixed cases. Hum. Pathol. 2010; 41; 163-171.
Cox R, Epstein JI. Large nested variant of urothelial carcinoma: 23 cases mimicking von Brunn nests and inverted growth pattern of noninvasive papillary urothelial carcinoma. Am. J. Surg. Pathol. 2011; 35; 1337-1342.
Amin MB, Reuter VE, Epstein JIet al. Bladder cancer. In Soloway S, Khoury A eds. Pathology Consensus Guidelines by the Pathology of Bladder Cancer Work Group. Paris: ICUD-EAU, 2012; 65-168.
Nishiyama N, Kitamura H, Maeda T et al. Clinicopathological analysis of patients with non-muscle-invasive bladder cancer: prognostic value and clinical reliability of the 2004 WHO classification system. Jpn J. Clin. Oncol. 2013; 43; 1124-1131.
Patschan O, Sjodahl G, Chebil G et al. A molecular pathologic framework for risk stratification of Stage T1 urothelial carcinoma. Eur. Urol. 2015; 68; 824-832.
Kang M, Jeong CW, Kwak C, Kim HH, Ku JH. Survival outcomes and predictive factors for female urethral cancer: long-term experience with Korean patients. J. Korean Med. Sci. 2015; 30; 1143-1149.
Brierley JD, Gospodarowicz MK, Wittekind CH. Union for International Cancer Control (UICC) TNM classification of malignant tumours. 8th ed. Oxford: Wiley-Blackwell, 2016.
Edge SE, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A eds. AJCC cancer staging manual. 7th ed. New York: Springer, 2010.
Union for International Cancer Control (UICC). TNM 8th edition errata. Union for International Cancer Contol (UICC). 2018. Available at: http://www.wileyanduicc.com/pdf/Corrected_pages.pdf (accessed February 2019).
Hu B, Djaladat H. Lymphadenectomy for testicular, penile, upper tract urothelial and urethral cancers. Curr. Opin. Urol. 2015; 25; 129-135.
Chandra A, Griffiths D, McWilliam LJ. Best practice: gross examination and sampling of surgical specimens from the urinary bladder. J. Clin. Pathol. 2010; 63; 475-479.
Van de Voorde W, Meertens B, Baert L, Lauweryns J. Urethral squamous cell carcinoma associated with urethral stricture and urethroplasty. Eur. J. Surg. Oncol. 1994; 20; 478-483.
Colapinto V, Evans DH. Primary carcinoma of the male urethra developing after urethroplasty for stricture. J. Urol. 1977; 118; 581-584.
Mohan H, Bal A, Punia RP, Bawa AS. Squamous cell carcinoma of the prostate. Int. J. Urol. 2003; 10; 114-116.
Arva NC, Das K. Diagnostic dilemmas of squamous differentiation in prostate carcinoma case report and review of the literature. Diagn. Pathol. 2011; 6; 46.
Wiener JS, Liu ET, Walther PJ. Oncogenic human papillomavirus type 16 is associated with squamous cell cancer of the male urethra. Cancer Res. 1992; 52; 5018-5023.
Thomas AA, Rackley RR, Lee U, Goldman HB, Vasavada SP, Hansel DE. Urethral diverticula in 90 female patients: a study with emphasis on neoplastic alterations. J. Urol. 2008; 180; 2463-2467.
Ahmed K, Dasgupta R, Vats A et al. Urethral diverticular carcinoma: an overview of current trends in diagnosis and management. Int. Urol. Nephrol. 2010; 42; 331-341.
Libby B, Chao D, Schneider BF. Non-surgical treatment of primary female urethral cancer. Rare Tumors 2010; 2; e55.
Lopez-Beltran A, Luque RJ, Mazzucchelli R, Scarpelli M, Montironi R. Changes produced in the urothelium by traditional and newer therapeutic procedures for bladder cancer. J. Clin. Pathol. 2002; 55; 641-647.
Oxley JD, Cottrell AM, Adams S, Gillatt D. Ketamine cystitis as a mimic of carcinoma in situ. Histopathology 2009; 55; 705-708.
Palou Redorta J, Schatteman P, Huguet Perez J et al. Intravesical instillations with bacillus Calmette-Guerin for the treatment of carcinoma in situ involving prostatic ducts. Eur. Urol. 2006; 49; 834-838.
Taylor JH, Davis J, Schellhammer P. Long-term follow-up of intravesical bacillus Calmette-Guerin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra. Clin. Genitourin. Cancer 2007; 5; 386-389.
Baker PM, Young RH. Radiation-induced pseudocarcinomatous proliferations of the urinary bladder: a report of 4 cases. Hum. Pathol. 2000; 31; 678-683.
Chan TY, Epstein JI. Radiation or chemotherapy cystitis with ‘pseudocarcinomatous’ features. Am. J. Surg. Pathol. 2004; 28; 909-913.